First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)Maja J.A. de Jonge, Víctor Moreno, Benedito A. Carneiro et al.|Blood|2019Cited by 11
Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinomaAnouk W. M. A. Schaeffers, Remco de Bree, Rebecca K. Stellato et al.|Oral Oncology Reports|2025Cited by 3